250 related articles for article (PubMed ID: 30851160)
1. AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients.
Daly AF; Rostomyan L; Betea D; Bonneville JF; Villa C; Pellegata NS; Waser B; Reubi JC; Waeber Stephan C; Christ E; Beckers A
Endocr Connect; 2019 Apr; 8(4):367-377. PubMed ID: 30851160
[TBL] [Abstract][Full Text] [Related]
2. Complicated Clinical Course in Incipient Gigantism Due to Treatment-resistant Aryl Hydrocarbon Receptor-Interacting Protein-mutated Pediatric Somatotropinoma.
van Santen SS; Daly AF; Buchfelder M; Coras R; Zhao Y; Beckers A; van der Lely AJ; Hofland LJ; Balvers RK; van Koetsveld P; van den Heuvel-Eibrink MM; Neggers SJCMM
AACE Clin Case Rep; 2022; 8(3):119-123. PubMed ID: 35602875
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
[TBL] [Abstract][Full Text] [Related]
5. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
[TBL] [Abstract][Full Text] [Related]
6. Pasireotide: a novel treatment for patients with acromegaly.
Cuevas-Ramos D; Fleseriu M
Drug Des Devel Ther; 2016; 10():227-39. PubMed ID: 26811671
[TBL] [Abstract][Full Text] [Related]
7. Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation.
Stelmachowska-Banaś M; Czajka-Oraniec I; Tomasik A; Zgliczyński W
Pituitary; 2022 Feb; 25(1):180-190. PubMed ID: 34498217
[TBL] [Abstract][Full Text] [Related]
8. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
[TBL] [Abstract][Full Text] [Related]
9. De-escalation treatment with pasireotide for acromegaly: a long-term experience.
Giampietro A; Menotti S; Chiloiro S; Pontecorvi A; De Marinis L; Bianchi A
Endocrine; 2023 Jun; 80(3):505-510. PubMed ID: 36808072
[TBL] [Abstract][Full Text] [Related]
10. The Effect of 6 Months' Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings.
Witek P; Bolanowski M; Szamotulska K; Wojciechowska-Luźniak A; Jawiarczyk-Przybyłowska A; Kałużny M
Front Endocrinol (Lausanne); 2021; 12():633944. PubMed ID: 33776927
[TBL] [Abstract][Full Text] [Related]
11. Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly.
Chang JS; Tseng HM; Chang TC
J Formos Med Assoc; 2016 Jun; 115(6):475-80. PubMed ID: 27117887
[TBL] [Abstract][Full Text] [Related]
12. Pasireotide in the Personalized Treatment of Acromegaly.
Puig-Domingo M; Bernabéu I; Picó A; Biagetti B; Gil J; Alvarez-Escolá C; Jordà M; Marques-Pamies M; Soldevila B; Gálvez MA; Cámara R; Aller J; Lamas C; Marazuela M
Front Endocrinol (Lausanne); 2021; 12():648411. PubMed ID: 33796079
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of long-acting pasireotide in acromegaly.
Akirov A; Gorshtein A; Dotan I; Khazen NS; Pauker Y; Gershinsky M; Shimon I
Endocrine; 2021 Nov; 74(2):396-403. PubMed ID: 34081309
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs.
Gadelha M; Bex M; Colao A; Pedroza García EM; Poiana C; Jimenez-Sanchez M; Yener S; Mukherjee R; Bartalotta A; Maamari R; Raverot G
Front Endocrinol (Lausanne); 2019; 10():931. PubMed ID: 32117045
[No Abstract] [Full Text] [Related]
15. Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study.
Lasolle H; Ferriere A; Vasiljevic A; Eimer S; Nunes ML; Tabarin A
Endocr Connect; 2019 Oct; 8(10):1383-1394. PubMed ID: 31518993
[TBL] [Abstract][Full Text] [Related]
16. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.
Freda PU; Katznelson L; van der Lely AJ; Reyes CM; Zhao S; Rabinowitz D
J Clin Endocrinol Metab; 2005 Aug; 90(8):4465-73. PubMed ID: 15886238
[TBL] [Abstract][Full Text] [Related]
17. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
Colao A; Auriemma RS; Pivonello R
Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466
[TBL] [Abstract][Full Text] [Related]
18. Successful medical management of a pituitary macroadenoma with features of resistant acromegaly and hyperprolactinemia using pasireotide.
Baagar KA; Sadiq A; Khan AA; Dabbous Z; Rohani Z
Qatar Med J; 2024; 2024(1):17. PubMed ID: 38654814
[TBL] [Abstract][Full Text] [Related]
19. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
McKeage K; Cheer S; Wagstaff AJ
Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
[TBL] [Abstract][Full Text] [Related]
20. Pasireotide: potential treatment option for McCune-Albright-associated acromegaly.
Ilie MD; Raverot G; Brac de la Perrière A
Eur J Endocrinol; 2024 Jan; 190(1):K17-K20. PubMed ID: 38128124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]